Adenosine 3',5'-cyclic monophosphate (cyclic AMP) (0.5 mg/kg) was infused into the carotid artery of baboons anesthesized with sodium pentobarbital, causing a biphasic increase in cerebral blood flow (CBF) and reduction in cerebrovascular resistance (CVR) associated in each phase with stimulation of cerebral metabolism evidenced by increased cerebral oxygen consumption (CMRO~) and cerebral glucose consumption (CMRGI). Intracarotid dibutyryl cyclic AMP (0.5 mg/kg) caused a monophasic increase in CBF and reduction of CVR but failed to alter cerebral metabolism. This may be due to its rapid removal from the circulation with ineffective passage across the blood-brain barrier since intracisternal infusion of dibutyryl cyclic AMP caused sustained increase in CBF, CMRO~ and CMRGI and reduction in CVR. Intracarotid AMP (0.4 mg/kg) and adenosine (0.3 mg/kg) caused an immediate and more marked increase in CBF and decrease in CVR unassociated with cerebral metabolic change making it unlikely that the observed effects of cyclic AMP can be attributed to its breakdown products. Cyclic AMP or its dibutyryl derivative may alter cerebral metabolism secondary to neuronal activation but increase in glucose/oxygen utilization ratio after intracarotid cyclic AMP and intracisternal dibutyryl cyclic AMP also suggests an influence on enzymatic regulation of glucose metabolism.
A DENOSINE 3',5'-cyclic monophosphate (cyclic AMP) has been implicated as the intracellular mediator for a variety of extracellular neurohumoral influences in mammalian and non-mammalian organisms, xe,~7 Mammalian brain has a great capacity for formation of cyclic AMP, the activity of the synthetic enzyme, adenyl cyclase, and the catabolizing enzyme, cyclic AMP phosphodiesterase, being much higher in the central nervous system (CNS) than in most other body tissues? as Extensive in vitro studies supported by limited studies in vivo have provided strong evidence that cyclic AMP plays a part in central and peripheral neurotransmission and probably plays some role in control of cerebral energy metabolism. 13 There has also been considerable interest in the possible role of cyclic AMP in vasomotor control? ,~Sa~ Evidence exists that alteration in the vascular tonus of systemic vascular beds may be due to stimulation of receptor sites by both neurogenic and humoral influences, the effects of which are apparently mediated by changes in intracellular cyclic AMP levels in the smooth muscle of the vessel wall. This paper reports measurements of the influence of exogenous cyclic AMP on cerebral hemodynamics and energy metabolism in vivo which hitherto have not been studied extensively in either primates or man.
Materials and Methods

Preparation of Material
Thirty-four adult baboons (Papio anubis) weighing 3.5 to 13 kg were anesthetized with intravenous pentobarbital 25 mg/kg body weight. Supplemental pentobarbital was given when required. After tracheostomy animals were immobilized with gallamine triethiodide (Flaxedil) 1 mg/kg body weight. Respiration with room air was maintained by a Harvard variable speed respirator.* End expiratory CO2 was monitored by a Beckman infrared gas analyzert and maintained at 3.5% to 4.5% in each animal (corresponding to PaCO2 of 33 to 45 mm Hg) by adjusting the rate and stroke volume of the respirator. The left femoral artery and vein were exposed and polyethylene catheters introduced into both vessels. Arterial blood pressure was recorded continuously from the descending aorta by means of a Statham pressure transducerS: connected to the femoral artery catheter. The venous catheter permitted intravenous infusion of drugs or fluids as required.
The extracranial vessels of the left and right side were exposed through a midline cervical incision. A thin polyethylene catheter was inserted into the right lingual artery to permit infusion of drugs to be tested. Otherwise, both external carotid arteries and branches were ligated bilaterally, together with the external jugular veins. The sympathetic and vagus nerves were carefully preserved, and special care was taken during *Variable speed respirator manufactured by Harvard Apparatus, Inc., 150 Dover Road, Millis, Massachusetts 02054.
"l'Infrared gas analyzer manufactured by Beckman Instruments, Inc., 2500 Harbor Boulevard, Fullerton, California 92634.
:I:P231A pressure transducer manufactured by Statham Laboratories, Inc., Hato Rey, Puerto Rico 00191. the entire operation to avoid excessive blood loss. Two electromagnetic flow probes connected to flow metersw were placed around both internal jugular veins, and cerebral blood flow (CBF) was continuously monitored as total cerebral venous outflow.
In six animals a laminectomy was performed at T1-2 and a thin polyethylene (PE 10) catheter was inserted in a cephalad direction through a perforation in the dura into the cisterna magna to permit infusion of the drugs to be tested. The thoracic laminectomy was performed to avoid any possibility of brain-stem trauma or cerebrospinal fluid (CSF) leakage that might occur from direct cisternal puncture. The perforation in the dura and the bone defects were sealed with Oxycel, and the muscle and skin incisions were sutured to prevent any leakage of spinal fluid. The catheter was fixed in place by inclusion in the suture line.
A catheter was wedged into the anterior third of the superior sagittal sinus through a midline frontal burr hole and connected to a pressure transducerll to measure superior sagittal sinus wedge pressure (SSSP). Another catheter was inserted into the sinus confluence through a second midline burr hole to permit cerebral venous blood sampling. For this purpose the animals were heparinized and sagittal sinus blood, together with blood sampled from the right brachial artery, was pumped at a rate of 5 ml/min by means of a Harvard Sigma pump through a Guyton oxygen analyzer* in order to monitor cerebral arteriovenous oxygen differences continuously. This blood was then returned to the body through a catheter placed in the right femoral vein. Samples of arterial and cerebral venous blood were also drawn into two *Values = mean -~ standard deviation, (-) sign denotes decrease; significant difference for A value (steady state) compared to A for saline group: w = p <0.05,11 = P <0.01. tTrCO2 = end expiratory CO2 (vol ~); N = number of monkeys tested; CBF = cerebral blood flow (ml/100 gm brain/min); MABP = mean arterial blood pressure (mm Hg); CVR = cerebral vascular resistance; G/O = glucose/oxygen ratio; CMRO~ = cerebral metabolic rate for oxygen (ml/100 gm brain/min); CMRGI = cerebral metabolic rate for glucose (ml/100 gm brain/min). :~0 --immediately after infusion completed.
0~
ml/min) for the continuous measurement of cerebral arteriovenous differences for glucose. All skull defects were sealed with acrylic cement. The right femoral artery was exposed and a catheter with a gas-permeable Teflon membrane was inserted into the abdominal aorta and connected to a mass spectrometer S for continuous analysis of PaCO~ and PaO~. We also measured PaCO2 and PaO2 together with pH intermittently by use of a Corning automatic blood gas analyzer.w Hematocrit and hemoglobin were also checked at intervals. The animal's temperature was maintained at 37 ~ C using a heating mattress. Electroencephalograph (EEG) and electrocardiogram (EKG) recordings were continuously monitored.
Animals were autopsied at the end of each experiment, and the brain was removed, weighed, and examined. One animal, in which the brain showed evidence of surgical trauma, and two with intracerebral hematoma were rejected from the study.
Experimental Protocol and Analysis of Data
Cyclic AMP (0.5 mg/kg), dibutyryl cyclic AMP (0.5 mg/kg), adenosine monophosphate (0.4 mg/kg), and adenosine (0.3 mg/kg) were each dissolved in 5 ml of 0.9% saline and infused into the internal carotid artery of 20 animals at the rate of 1 ml/min over a.5-minute interval using the Harvard infusion pump. For purposes of comparing control measurements, the saline solvent of the active substances was also infused at an identical rate. Parameters were continuously recorded and significance of change was calculated immediately and at intervals after infusion for a period of 45 minutes or until a return to preinfusion values was established.
In six animals dibutyryl cyclic AMP (0.5 mg/kg body weight) was dissolved in 0.5 ml of 0.9% saline and infused into the cisterna magna at a rate of 0.1 ml/min over a 5-minute interval by means of a Harvard infusion pump. For purposes of control measure- ments, the saline solvent of the active substance was infused at an identical rate. Parameters were continuously recorded during and at intervals after infusion for a period of 30 minutes or until a return to preinfusion values was again established.
Cerebral blood flow was calculated per 100 gm brain tissue/min. Cerebral perfusion pressure (CPP) was calculated by subtracting SSSP from mean arterial blood pressure (MABP). Cerebrovascular resistance (CVR) was calculated from the formula: CVR = CPP/CBF. Cerebral oxygen consumption (CMRO~) was calculated as the product of CBF and arteriovenous oxygen differences. Cerebral glucose consumption (CMRG1) was calculated as the product of CBF and arteriovenous glucose differences. The glucose/oxygen (G/O) ratio was determined from both measurements.
The Student t-test was used for analyzing significance of change of the parameters measured from the steady state (/x value) for the two groups of animals receiving cyclic AMP and dibutyryl cyclic AMP. Steadystate values were measured at the same intervals of time during and after a comparable infusion of saline. The paired t-test was used to analyze the significance of change from steady-state values after intracarotid saline, adenosine monophosphate, and adenosine, and after intracisternal dibutyryl cyclic AMP infusion. Significant differences were considered to be present with a 5% level of confidence or better.
Results
Control Solutions
In eight monkeys internal carotid infusion of control saline solutions produced no significant alteration of cerebral hemodynamics and metabolism, and only minimal reduction in MABP 45 minutes after infusion.
lntracarotid Cyclic AMP
Results of intracarotid cyclic AMP infusion (0.5 mg/kg) in nine animals are given in Table 1 . An apparently biphasic alteration in cerebral hemodynamics and metabolism was observed. There was a temporary increase in CBF immediately after infusion. Fifteen to 30 minutes after infusion ceased there was a more sustained CBF increase and reduction in CVR. Coincidental with CBF increase, a biphasic increase in CMRO2 and CMRG1 was also observed. The G/O ratio temporarily increased immediately after infusion.
The effects of intracarotid cyclic AMP (5 mg/kg) infused 1 hour after the 0.5 mg/kg dose in four animals of the same group did not significantly differ from lower dosages. Steady-state CBF values were, however, elevated (48.1 4-9.3 vs 36.3 + 7.1 ml/100gm brain/min), suggesting a continued effect of the cyclic AMP injected 1 hour previously. Thus, comment on dose-response relationships is not possible. Results with higher doses of cyclic AMP suggest either a tachyphylactic response to repeat cyclic AMP infusion or else that movement of cyclic AMP into brain and CSF occurs via a saturable mechanism.
Intracarotid Dibutyryl Cyclic AMP
In a separate group of eight animals, dibutyryl cyclic AMP (0.5 mg/kg) increased CBF only 5 minutes after infusion ceased (Table 2) . Unlike cyclic AMP, dibutyryl cyclic AMP caused a significant fall in blood pressure 15 minutes after infusion, the fall continuing throughout the period of observation. However, CVR decreased significantly. Since CMRO2 did not change, the observed effects on CBF and CVR are best explained by a primary effect of the drug in reducing cerebral vasomotor tone. In the absence of any change in CMRO2 the temporary increase in CMRGI immediately after infusion seems due to the sudden rise in arterial blood glucose levels that occurred with dibutyryl cyclic AMP infusion (Fig. 1 , see Discussion).
Intracarotid Adenosine Monophosphate and Adenosine
Near equivalent doses of AMP and adenosine were infused into the carotid artery in a separate group of six animals. Because of technical difficulties, CMRGI was not measured in this group of experiments. During the infusion of AMP (0.4 mg/kg), CBF immediately increased despite a significant fall in blood pressure so that CVR became reduced (Fig. 2) . Five minutes after infusion both CBF and blood pressure had recovered to steady-state values. Identical changes were seen after infusion of adenosine (0.3 mg/kg) (see Fig. 2 ), except that hypotension continued throughout the period of observation. The CMROu showed no significant change in either group of animals. Absence of alteration in CMROz by either AMP or adenosine makes it unlikely that the observed effects of cyclic AMP can be attributed to its breakdown products.
Intracisternal Dibutyryl Cyclic AMP
An increase in CBF was seen during and for 30 minutes after intracisternal infusion of dibutyryl cyclic AMP (0.5 mg/kg body weight) (Fig. 3) . Mean arterial blood pressure (MABP) became significantly reduced 30 minutes after infusion ceased; CVR was markedly reduced during the infusion and remained so throughout the entire 35-minute interval of observation; and CMRO2 became significantly increased during the infusion and up to 20 minutes after infusion was completed. The maximal increase in CMRO2 recorded at the 20-minute interval was coincidental with the maximal increases in CBF. Apart from minimal but temporary increases in SSSP during intracisternal infusion, control solutions of the saline solvent produced no significant change in CBF.
No changes in the EEG were observed in any experiment. also cause vasodilatation mediated via an increase in intracellular cyclic AMP. 7 Mechanisms by which cyclic AMP may bring about vasodilatation are unproven, but the cyclic nucleotide may stimulate membrane Na § K § causing reduction of intracellular Na § available for Ca § exchange so that intracellular Ca + § and hence vascular tone decrease?
In vivo studies of the effects of exogenous cyclic AMP on cerebral vessels have been surprisingly limited. However, in studies with cats and monkeys, Peterson, et al., al described alleviation of basilar artery spasm caused by subarachnoid hemorrhage when dibutyryl cyclic AMP was irrigated directly onto the vessel wall. Effects of cyclic AMP on the cerebral vasculature thus appear to be in accord with dilator effects observed in other vascular beds.
In the present experiments the CBF increase produced by intracarotid dibutyryl cyclic AMP was associated only with reduced CVR, which suggests a primary effect of the cyclic nucleotide derivative on cerebral resistance vessels. On the other hand, the CBF increase produced by cyclic AMP was accompanied by coincidental increase of CMRO2 and CMRG1. Since CBF may increase secondary to stimulation of cerebral metabolism, 9 any additional primary effect of cyclic AMP on the cerebral vasculature cannot therefore be directly established.
Doses of cyclic AMP employed in the current experiments were high (up to 300-fold) compared to physiological circulating levels in the baboon (20 to 40 picomole/ml). We do not believe that this alters the relevance of our observations since cyclic AMP synthesized intracellularly may reach higher concentrations than can be attained by uptake from the circulation. Infusion of lower doses of cyclic and dibutyryl cyclic AMP in early experiments produced no measurable effects on CBF and metabolism. It seems unlikely that CBF and metabolism are influenced by circulating cyclic AMP levels in the physiological range.
Due to its greater lipid solubility the dibutyryl derivative of cyclic AMP may pass more readily across cell membranes than cyclic AMP. 14 In view of this the failure of intracarotid dibutyryl cyclic AMP to stimulate cerebral metabolism in the current experiments was somewhat surprising. Although circulating levels were not measured, it is possible that dibutyryl cyclic AMP was more rapidly removed from the circulation than cyclic AMP because of greater uptake into peripheral tissues. This plus slow penetration of the blood-brain barrier may have led to inadequate cerebral uptake of dibutyryl cyclic AMP to explain the lack of alteration in cerebral metabolism. To support this, in a number of early experiments insufficient for statistical analysis, increase of CMRO2 and CMRG1 was seen after intracarotid injection of larger concentrations of dibutyryl cyclic AMP. Furthermore, there was sustained increase in CMRO2 and CMRG1 as well as CBF when dibutyryl cyclic AMP was infused intracisternally, thereby bypassing the bloodbrain barrier.
The sudden, marked rise in arterial glucose levels during and immediately after intracarotid dibutyryl cyclic AMP infusion may explain the transient increase in CMRG1 without change in CMRO2 seen only immediately after infusion. When such large and rapid rises of glucose levels occur in arterial blood, glucose may move across the bloodbrain barrier into brain stores as well as CSF without being used for glucose oxidative metabolism? ~ Although arterial glucose levels showed some rise, the same argument could not be applied to the increased CMRG1 measured after cyclic AMP infusion since this increase was sustained and associated with increased CMRO~. Infusion of glucose solutions in the same animal model has never been found to alter CMRO2 (unpublished observations).
The rise of glUcose levels in arterial blood after infusion of cyclic and dibutyryl cyclic AMP is, for the most part, attributed to activation of hepatic glycogenolysis? Difference in the rate and extent of the rise (46% to 100% after dibutyryl cyclic AMP compared to 13% to 25% after cyclic AMP) may be explained by more efficient cellular penetration by dibutyryl cyclic AMP in combination with its delayed intracellular enzymic deactivation? ~ An alternative explanation might involve differing effects of the two nucleotides on insulin secretion, with cyclic AMP causing a larger insulin response and consequently less elevation of glucose levels than dibutyryl cyclic AMP. This raises the issue that the observed metabolic effect of cyclic AMP might be secondary to increased insulin secretion since insulin has been claimed to increase cerebral glucose utilization, 6 but this explanation seems unlikely since cyclic AMP also increased CMRO~. Furthermore, previous studies from this laboratory have shown no effect of insulin on cerebral glucose and oxygen consumption? ~ It is difficult to attribute the second of the biphasic changes after intracarotid cyclic AMP to a direct effect on CBF and metabolism since cyclic AMP is subjected to rapid intracellular enzymic inactivation. Some quantity of cyclic AMP may have moved directly into CSF during and soon after infusion, followed by delayed uptake into cerebral tissue. Alternatively, secondary release of some other unidentified factor or factors into the circulation may have caused the delayed flow and metabolic effects.
Stimulation of metabolism by cyclic AMP may be entirely secondary to enhanced neuronal activityY, 4 Although no supporting changes in EEG activity were seen, these may have been masked by barbiturate anesthesia.
However, intracarotid cyclic AMP and intracisternal dibutyryl cyclic AMP increased the cerebral glucose/oxygen utilization ratio as well as CMRO~ and CMRG1, indicating that stimulation of both aerobic and anaerobic glucose metabolism took place. This would suggest that cyclic AMP may also influence enzymatic regulation of cerebral glucose metabolism.
